Influenza A virus H1N1 vaccine - CEL-SCI

Drug Profile

Influenza A virus H1N1 vaccine - CEL-SCI

Alternative Names: L.E.A.P.S. swine flu vaccine - CEL-SCI; LEAPS-H1N1; LEAPS-H1N1-DC

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CEL-SCI Corporation
  • Developer CEL-SCI Corporation; Johns Hopkins University
  • Class Influenza A virus H1N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Influenza A virus H1N1 subtype

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Influenza-A-virus-H1N1-subtype in USA (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Influenza-A-virus-H1N1-subtype(Prevention) in USA (Parenteral)
  • 14 Apr 2014 Phase-I clinical trials in Influenza-A virus H1N1 subtype (in hospitalised patients) in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top